Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2,3-dimethoxy-5-methyl-6-decaprenylbenzoquinone
2. Bio-quinone Q10
3. Co-enzyme Q10
4. Coenzyme Q10, (z,z,z,z,z,z,e,e,e)-isomer
5. Coenzyme Q10, Ion (1-), (all-e)-isomer
6. Coq 10
7. Coq10
8. Q-ter
9. Ubidecarenone
10. Ubiquinone 10
11. Ubiquinone 50
12. Ubiquinone Q10
13. Ubisemiquinone
14. Ubisemiquinone Radical
1. Ubidecarenone
2. 303-98-0
3. Ubiquinone-10
4. Coq10
5. Ubiquinone 50
6. Neuquinon
7. Ubiquinone Q10
8. Ubiquinone
9. Justquinon
10. Neuquinone
11. Emitolon
12. Heartcin
13. Inokiten
14. Terekol
15. Udekinon
16. Coenzyme Q-10
17. Vitamin Q
18. Coenzyme Q
19. Coenzyme-q10
20. Bio-quinone Q10
21. Unispheres Q 10
22. Co-enzyme Q10
23. Coenzyme Q 10
24. Puresorb Q 40
25. Aqua Q10
26. Adelir
27. Nsc 140865
28. Oristar Ubq
29. Q 199
30. Api-31510
31. Ube-q
32. Coenzyme Q-199
33. Bpm-31510
34. Nsc-140865
35. Bpm31510
36. Q 10aa
37. 2-((2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaen-1-yl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
38. Chebi:46245
39. Ej27x76m46
40. Ubidecarenone For System Suitability
41. Api 31510
42. Nsc-140665
43. 2-[(2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaenyl]-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
44. Ncgc00159429-02
45. Luvacor
46. Dsstox_cid_26054
47. Dsstox_rid_81308
48. Dsstox_gsid_46054
49. (all-e)-2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione
50. 2,5-cyclohexadiene-1,4-dione, 2-((2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl
51. 2,5-cyclohexadiene-1,4-dione, 2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-, (all-e)-
52. 2-((all-e)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-p-benzoquinone
53. 2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-p-benzoquinone
54. P-benzoquinone, 2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-
55. Coq 10
56. Bio-quinon
57. Ubidecarenona
58. Ubidecarenonum
59. Ubidecarenonum [latin]
60. Coenzyme Q(sub 10)
61. Ubidecarenona [spanish]
62. Coq(sub 10)
63. Ubiquinone Q(sub 10)
64. Cas-303-98-0
65. Ccris 9016
66. Co-enzyme Q-10
67. Einecs 206-147-9
68. Co Q10
69. Unbiquinone
70. Armolipid
71. Kudesan
72. Mitocor
73. Akvion
74. Unii-ej27x76m46
75. Nsc140865
76. Liquid-q
77. Ubiquinone-q10
78. Ubidecarenone [inn:ban:jan:nf]
79. Ubiquinone(10)
80. Ncgc00095322-03
81. Kanekaq10
82. 2,5-cyclohexadiene-1,4-dione, 2-((2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-
83. 2-((2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaenyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
84. 2-[(2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaen-1-yl]-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
85. All-trans-ubiquinone
86. Li-q-sorb
87. Q-gel
88. Adelir (tn)
89. Coenzymeq10,(s)
90. Kaneka Q10
91. Mfcd00042919
92. Bp31510
93. Co Enzyme Q-10
94. Ubiquinone [inci]
95. Coq10; Ubiquinone-10
96. Coenzyme Q10(coq10)
97. Aqua Q 10l10
98. Ubidecarenone [dsc]
99. Ubidecarenone [inn]
100. Ubidecarenone [jan]
101. Ubidecarenone (jp17/inn)
102. Q-gel 100
103. Schembl19858
104. Mls000028745
105. Ubidecarenone [mart.]
106. Ubiquinone 50 [mi]
107. Voriconazole Impurity C
108. Coenzyme Q10 [vandf]
109. Ubidecarenone [usp-rs]
110. Ubidecarenone [who-dd]
111. Chembl454801
112. (non-labelled)coenzyme Q10-d5
113. Dtxsid6046054
114. Schembl11901691
115. Ex-a973
116. Coenzyme Q10, Analytical Standard
117. Hy-n0111
118. Tox21_111660
119. Tox21_113394
120. Ubidecarenone [ep Monograph]
121. Lmpr02010001
122. S2398
123. Zinc85427689
124. Coenzyme Q10, >=98% (hplc)
125. Akos015897104
126. Akos015951232
127. Ac-4352
128. Db09270
129. 2-(3,7,11,15,19,23,27,31,35,39-decamethyl-tetraconta-2,6,10,14,18,22,26,30,34,38-decaenyl)-5,6-dimethoxy-3-methyl-[1,4]benzoquinone
130. 2-[(2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione
131. As-13341
132. Ls-15517
133. Q 10
134. Q-10
135. Smr000058651
136. C1971
137. Cs-0007796
138. N1796
139. C-7060
140. D01065
141. 303c980
142. A936217
143. Q321285
144. Ubidecarenone For System Suitability [usp-rs]
145. Ubidecarenone, European Pharmacopoeia (ep) Reference Standard
146. Ubidecarenone, United States Pharmacopeia (usp) Reference Standard
147. 2-deca(3-methylbut-2-enylene)-5,6-dimethoxy-3-methyl-p-benzoquinone
148. Coenzyme Q10 Solution, 1 Mg/ml In Ethanol, Certified Reference Material, Ampule Of 1 Ml
149. Ubidecarenone For System Suitability, European Pharmacopoeia (ep) Reference Standard
150. Ubidecarenone For System Suitability, United States Pharmacopeia (usp) Reference Standard
151. (all-e)-2,3-dimethoxy-5-methyl-6-(3,7,11,15,19,23,27,31-octamethyl-2,6,10,14,18,22,26,30-dotriacontaoctaenyl)-2,5-cyclohexadiene-1,4-dione
152. 2,4-dione, 2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-
153. 2,4-dione, 2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-, (all-e)-
154. 2,5-cyclohexadiene-1,4-dione, 2-((2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl)-5,6-dimethoxy-3-methyl-
155. 2,5-cyclohexadiene-1,4-dione, 2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-, (all Trans)-
156. 2-((all-e)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione
157. 2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-p-benzoquinone, (all Trans)-
158. 2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecenyl)-5,6-dimethoxy-3-methyl-1,4-benzoquinone
159. 2-[(2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl]-5,6-dimethoxy-3-methyl- 2,5-cyclohexadiene-1,4-dione
160. 2-[(2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl]-5,6-dimethoxy-3-methylbenzo-1,4-quinone #
161. P-benzoquinone,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-
| Molecular Weight | 863.3 g/mol |
|---|---|
| Molecular Formula | C59H90O4 |
| XLogP3 | 19.4 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 31 |
| Exact Mass | 862.68391135 g/mol |
| Monoisotopic Mass | 862.68391135 g/mol |
| Topological Polar Surface Area | 52.6 Ų |
| Heavy Atom Count | 63 |
| Formal Charge | 0 |
| Complexity | 1840 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 9 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
The diet supplements containing ubidecarenone are indicated, as stated in the product label, to assist individuals with cardiovascular complaints including congestive heart failure and systolic hypertension. In the product, ubidecarenone is used to increase the cardiac input as well as for the prevention of several other diseases like Parkinson, fibromyalgia, migraine, periodontal disease and diabetes, based on preclinical studies. It is important to highlight that these products are not FDA approved and it is recommended to use under discretion.
Ubidecarenon has roles in many prysiological process including sulfide oxidation, regulation of mitochondrial permeability transition pore and translocation of protons and calcium ions accross biological membranes. Studies have shown its benefitial effect in treating cancer, statin myopathy, congestive heart failure and hypertension.
Vitamins
Organic substances that are required in small amounts for maintenance and growth, but which cannot be manufactured by the human body. (See all compounds classified as Vitamins.)
C - Cardiovascular system
C01 - Cardiac therapy
C01E - Other cardiac preparations
C01EB - Other cardiac preparations
C01EB09 - Ubidecarenone
Absorption
Ubidecarenone is absorbed from the small intestine into the lymphatics and then it can enter the blood. The hydrophobicity and large molecular weight limit its absorption making it very poor and variable depending on the food intake and the number of lipids presented in the food. The absorption is lower in the presence of an empty stomach and greater in presence of high lipid food diet. The daily dosage of ubidecarenone presents the reach of maximal serum concentration by reaching a plateau after three weeks. The pharmacokinetic properties may vary between different brands but studies have reported an AUC of 11.51 mcg h/ml and a Cmax of 0.32 mcg/ml at a time of 7.9 h.
Route of Elimination
The main elimination route of ubidecarenone is through the bile. After its oral administration, over 60% of the dose is excreted in the feces in the form of unchanged ubidecarenone and a small fraction of the metabolites. In the urine, ubidecarenone is bound to saposin B protein and represents only 8.3% of the total administered dose.
Volume of Distribution
Ubidecarenone is distributed to the various tissues of the body and it is able to enter the brain. In preclinical studies with intravenous administration of ubidecarenone, it is reported a volume of distribution of 20.4 L/kg which reflects its ability to penetrate extensively into organs and tissues. AS a general rule, tissues with high-energy requirements or metabolic activity tend to presents higher amounts of ubidecarenone, these organs can be heart, kidney, liver and muscle.
Clearance
In preclinical studies with intravenous administration of ubidecarenone, it is reported a total clearance of 1.18 ml h/kg which was indicative of a prolonged elimination.
Studies indicate that there is no saturation process during the metabolism of ubidecarenone. It is metabolized in all tissues by the phosphorylation in the cells and transportation to the kidneys for further excretion by the urine. After exerting its action, ubidecarenone is reduced and forms hydroquinone which is capable of recycling and regenerates other antioxidants such as tocopherol and ascorbate. The later metabolism of hydroquinone generates the formation of Q acid I and Q acid II in free and conjugated forms.
The pharmacokinetic properties may vary between different brands but studies have reported a half-life of ubidecarenone of 21.7 h.
Ubidecarenone is an essential cofactor in the mitochondrial electron transport chain. Its functions are the acceptance of electrons from the complex I and II and this activity is vital for the production of ATP. It acts as a mobile redox agent shuttling electrons and protons in the electron transport chain. Ubidecarenone also presents antioxidant activity in mitochondria and cellular membranes, protecting against peroxidation of lipid membranes as well as inhibiting oxidation of LDL-cholesterol.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Listed Suppliers
Basic Nutrition, your expert for sourcing from China, India and Europe.
About the Company : As an ISO9001, ISO22000 certificated supplier, Basic Nutrition supply high-quality ingredients for nutraceuticals. We can offer a range of products from small to large quantites: h...
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
About the Company : Established in 1994, Rochem is a distributor of pharmaceutical, food, nutritional and animal health ingredients to some of the largest companies in the world. It sources high-quali...
Jai Radhe Sales is your partner for all your sourcing needs.
About the Company : Jai Radhe Sales was founded in 1999 as an out-of-the-box distribution firm specializing in the global supply of high-quality pharmaceutical ingredients. The firm provides complete ...
Pharm-Rx is a reputed global importer and distributor of pharmaceutical active ingredients.
About the Company : Pharm-Rx has earned an outstanding reputation since its establishment in 1991, serving as a reputable importer and distributor of active ingredients to the pharmaceutical, nutritio...
About the Company : Allastir instituted the services in 2010 with a motive to cater the pharmaceutical industry with niche API's. In Allastir we strongly believe in team work and customer satisfaction...
About the Company : Anthem Biosciences is a leading contract research and innovation service provider (CRISP) in Bengaluru, India, which manufactures novel drug actives. Established in 2007, it specia...
About the Company : HANGZHOU THINK CHEMICAL CO., LTD. (THINKCHEM) is an integrative corporation of trade, research and contract manufacture. With about ten years of business experiences on the marketi...
About the Company : PK Components is a Polish distributor of raw materials for the production of dietary supplements and for the food industry. Our hallmark is a stable market position, customer trust...
About the Company : Summit ingredient Co.,Ltd is a leading and rapidly growing company wh ich engages in the production, development, source and sale of botanical extracts . Summit located in Shaanxi ...
About the Company : Zenfold Sustainable Technologies (ZST) is a specialty and fine chemicals company, established in 2021. Our advanced technological capabilities and state-of-the-art infrastructure a...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
Through the acquisition, addition of Qunol’s CoQ10 (ubiquinone) and Turmeric products strengthens Sanofi’s CHC Vitamin, Mineral and Supplements category, one of the largest and fastest-growing consumer health categories in the US.
Lead Product(s): Coenzyme Q10,Vitamin E
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Qunol CoQ10
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 29, 2023
Lead Product(s) : Coenzyme Q10,Vitamin E
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Sanofi
Deal Size : Undisclosed
Deal Type : Acquisition
Sanofi Completes Acquisition of Qunol®
Details : Through the acquisition, addition of Qunol’s CoQ10 (ubiquinone) and Turmeric products strengthens Sanofi’s CHC Vitamin, Mineral and Supplements category, one of the largest and fastest-growing consumer health categories in the US.
Brand Name : Qunol CoQ10
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 29, 2023
Details:
Through the acquisition, addition of Qunol’s CoQ10 (ubiquinone) and Turmeric products strengthens Sanofi’s CHC Vitamin, Mineral and Supplements category, one of the largest and fastest-growing consumer health categories in the U.S.
Lead Product(s): Coenzyme Q10,Vitamin E
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Qunol CoQ10
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 27, 2023
Lead Product(s) : Coenzyme Q10,Vitamin E
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Sanofi
Deal Size : Undisclosed
Deal Type : Acquisition
Sanofi to Acquire Qunol®, a Fast-Growing U.S. Brand in the Healthy Aging Segment
Details : Through the acquisition, addition of Qunol’s CoQ10 (ubiquinone) and Turmeric products strengthens Sanofi’s CHC Vitamin, Mineral and Supplements category, one of the largest and fastest-growing consumer health categories in the U.S.
Brand Name : Qunol CoQ10
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 27, 2023
Details:
The collaboration is for BPGbio’s BPM 31510 for Epidermolysis Bullosa Phase II/III trial. Debra of America will provide support to awareness, understanding, and key information towards patient recruitment and advocacy for the clinical trial.
Lead Product(s): Coenzyme Q10
Therapeutic Area: Rare Diseases and Disorders Brand Name: BPM31510
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Debra of America
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 27, 2023
Lead Product(s) : Coenzyme Q10
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Debra of America
Deal Size : Undisclosed
Deal Type : Partnership
Details : The collaboration is for BPGbio’s BPM 31510 for Epidermolysis Bullosa Phase II/III trial. Debra of America will provide support to awareness, understanding, and key information towards patient recruitment and advocacy for the clinical trial.
Brand Name : BPM31510
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 27, 2023
Details:
Under the licensing agreement Clarus will develop and commercialize McGill’s proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans with Coenzyme-Q10 (Ubiquinone).
Lead Product(s): Coenzyme Q10,Caspofungin
Therapeutic Area: Genetic Disease Brand Name: Ubiquinone
Study Phase: DiscoveryProduct Type: Small molecule
Sponsor: Clarus
Deal Size: $40.8 million Upfront Cash: $0.4 million
Deal Type: Licensing Agreement September 16, 2021
Lead Product(s) : Coenzyme Q10,Caspofungin
Therapeutic Area : Genetic Disease
Highest Development Status : Discovery
Partner/Sponsor/Collaborator : Clarus
Deal Size : $40.8 million
Deal Type : Licensing Agreement
Details : Under the licensing agreement Clarus will develop and commercialize McGill’s proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans with Coenzyme-Q10 (Ubiquinone).
Brand Name : Ubiquinone
Molecule Type : Small molecule
Upfront Cash : $0.4 million
September 16, 2021
Details:
Ubiquinol (the active form of CoQ10) significantly improved FMD in both treated groups compared with the placebo group (Ubiquinol 200 mg/day; Ubiquinol 100 mg/day; placebo).
Lead Product(s): Coenzyme Q10
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Ubiquinol
Study Phase: UndisclosedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2020
Lead Product(s) : Coenzyme Q10
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Ubiquinol (the active form of CoQ10) significantly improved FMD in both treated groups compared with the placebo group (Ubiquinol 200 mg/day; Ubiquinol 100 mg/day; placebo).
Brand Name : Ubiquinol
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 05, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Market Place
ABOUT THIS PAGE
A Coenzyme Q10 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Coenzyme Q10, including repackagers and relabelers. The FDA regulates Coenzyme Q10 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Coenzyme Q10 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Coenzyme Q10 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Coenzyme Q10 supplier is an individual or a company that provides Coenzyme Q10 active pharmaceutical ingredient (API) or Coenzyme Q10 finished formulations upon request. The Coenzyme Q10 suppliers may include Coenzyme Q10 API manufacturers, exporters, distributors and traders.
click here to find a list of Coenzyme Q10 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Coenzyme Q10 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Coenzyme Q10 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Coenzyme Q10 GMP manufacturer or Coenzyme Q10 GMP API supplier for your needs.
A Coenzyme Q10 CoA (Certificate of Analysis) is a formal document that attests to Coenzyme Q10's compliance with Coenzyme Q10 specifications and serves as a tool for batch-level quality control.
Coenzyme Q10 CoA mostly includes findings from lab analyses of a specific batch. For each Coenzyme Q10 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Coenzyme Q10 may be tested according to a variety of international standards, such as European Pharmacopoeia (Coenzyme Q10 EP), Coenzyme Q10 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Coenzyme Q10 USP).
LOOKING FOR A SUPPLIER?
